GlassScriptPhysician profile
Ramin Tayani
NPI 1265528970
$19,232.98
in general payments reported to CMS, 2019-2025
32 companies · $4,004 in 2025
The $4,004 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,059 · 2020: $4,733 · 2021: $740 · 2022: $1,817 · 2023: $2,619 · 2024: $3,260 · 2025: $4,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,723 · Entertainment: $688 · Travel and Lodging: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,722.79 |
| Entertainment | $687.75 |
| Travel and Lodging | $472.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,072.04 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Aesculap, INC. | $3,811.91 | 2020 | |
| Abbvie INC. | $1,247.26 | 2023-2025 | Durysta, Botox |
| Oyster Point Pharma, INC. | $869.30 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $780.81 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Optos, INC. | $730.65 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $529.20 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $428.54 | 2024-2025 | Xiidra, Miebo, Envista Envy |
| Horizon Therapeutics Plc | $402.22 | 2019-2023 | Tepezza |
| Glaukos Corporation | $300.64 | 2019-2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $290.08 | 2019-2025 | |
| Harrow Eye, LLC | $281.86 | 2023-2025 | Iheezo, Vevye |
| Kala Pharmaceuticals, INC. | $273.83 | 2019-2022 | |
| Amgen INC. | $238.18 | 2024-2025 | Tepezza |
| Nova Eye, INC. | $225.00 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $216.28 | 2019-2023 | Dextenza |
| New World Medical,INC. | $213.69 | 2019-2025 | Streamline, Clearpath, Via360 |
| Lumenis, INC | $205.16 | 2019 | |
| Ani Pharmaceuticals, INC. | $150.17 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $149.02 | 2019-2022 | |
| Biotissue Holdings INC. | $139.08 | 2024 | |
| Shire North American Group INC | $117.73 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $116.35 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Dompe US, INC. | $94.44 | 2025 | Oxervate |
| Thea Pharma INC. | $82.03 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $65.96 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.32 | 2021 | |
| Osteocentric Technologies, INC. | $51.23 | 2023 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Maculogix, INC. | $33.97 | 2020 | |
| Sight Sciences, INC. | $33.86 | 2021 | |
| Beaver-Visitec International, INC. | $19.34 | 2023 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Tayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.